Search

Your search keyword '"De Socio, G. V."' showing total 3 results
Start Over Author "De Socio, G. V." Language undetermined
3 results on '"De Socio, G. V."'

1. Pre and Post-Monoclonal Infusion Neutralizing Activity in a Subgroup of Patients Treated in the Presence of two SARS-CoV-2 Dominant Variant of Concern (VOCs) and an Ongoing Vaccination. Overall Clinical Efficacy of Two Monoclonal Antibodies Association in Umbria

Author

Schiaroli, E., De Socio, G. V., Gidari, A., Malincarne, L., Benedetti, S., Lanzi, A., Bastianelli, S., Pierucci, S., Busti, C., Fagotti, B., Vicenti, I., Zazzi, M., and Francisci, D.

Subjects
Neutralizing activity, COVID19, VOCs, mAbs
Abstract

In patients with mild-to-moderate COVID-19 and at high risk of progression, casirivimab/imdevimab and bamlanivimab/etesivimab were utilized in Umbria from late April to November 2021. This period was characterized by an initial prevalence of alpha (B1.1.1.7) and its progressive substitution with the delta variant (B1.617.2). Many delta infections occurred in patients already recently vaccinated.Our study aimed to observe the clinical outcome of patients treated with mAbs associations in a subgroup in which viral isolation was obtained, the pre and post-infusion neutralizing antibody activity against their viral isolate.In this retrospective observational study, the clinical outcome before and 30 days after infusion, the baseline neutralizing activity of sera against their viral isolate, and the titers of neutralizing antibodies (NAbTs) one-hour post-infusion relative to the type of mAbs associations were evaluated.Better efficacy of the mAbs combinations relative to monotherapy regarding global hospitalization (Alpha infections occurred prevalently in unvaccinated patients or after 5-6 months, while delta infections prevailed in vaccinated ones. A poor neutralizing activity in most of these patients was seen. A higher NAbT after infusion of casirivimab/imdevimab was observed.

Published
2022

2. Dolutegravir safety in a real-life setting: results Title from the SCOLTA cohort

Author

G. Madeddu, M. S. Mameli, N. Squillace, B. Menzaghi, R. Gulminetti, G. V. De Socio, A. Di Biagio, G. C. Orofino, G. Pellicanò, B. M. Celesia, L. Calza, C. Martinelli, S. Rusconi, A. Cascio, F. Vichi, G. Cenderello, L. Valsecchi, P. Maggi, G. Angioni, C. Dentone, K. Falasca, E. Ricci, P. Bonfanti, Castagna A, D'Arminio A, Puoti M, Rizzardini G., Madeddu, G., Mameli, M. S., Squillace, N., Menzaghi, B., Gulminetti, R., De Socio, G. V., Di Biagio, A., Orofino, G. C., Pellicanò, G., Celesia, B. M., Calza, L., Martinelli, C., Rusconi, S., Cascio, A., Vichi, F., Cenderello, G., Valsecchi, L., Maggi, P., Angioni, G., Dentone, C., Falasca, K., Ricci, E., and Bonfanti, P.

Published
2019

3. Raltegravir-based therapy in a cohort of HIV/HCV co-infected individuals

Author

Paolo Maggi, M. Franzetti, G. V. De Socio, Tiziana Quirino, Giovanni Penco, A. Di Biagio, Chiara Dentone, Elena Ricci, G. Orofino, Paolo Bonfanti, Lucia Taramasso, Simone Passerini, Barbara Menzaghi, Canio Martinelli, Raffaella Libertone, Benedetto Maurizio Celesia, Giordano Madeddu, Taramasso, L, Madeddu, G, Ricci, E, De Socio, G, Menzaghi, B, Orofino, G, Passerini, S, Franzetti, M, Maggi, P, Dentone, C, Martinelli, C, Celesia, B, Penco, G, Libertone, R, Quirino, T, Bonfanti, P, Di Biagio, A, De Socio, G V, and Celesia, B M

Subjects
Male, HIV Infections, medicine.disease_cause, Hepatitis, Cohort Studies, HIV Infection, Viral, Pyrrolidinone, Univariate analysis, Coinfection, Hazard ratio, virus diseases, Alanine Transaminase, General Medicine, Middle Aged, Tolerability, Hepatitis C, Pyrrolidinones, Liver, HCV, Cohort, RNA, Viral, Female, Safety, Human, medicine.drug, medicine.medical_specialty, Efficacy, Hepatitis C virus, Hepatiti, Follow-Up Studie, Raltegravir Potassium, Internal medicine, medicine, Humans, Aspartate Aminotransferases, Adverse effect, Demography, Pharmacology, business.industry, Aspartate Aminotransferase, medicine.disease, Raltegravir, Immunology, RNA, Cohort Studie, Follow-Up Studies, business
Abstract

The relationship between hepatic tolerance and hepatitis C virus (HCV) co-infection has not been extensively studied in clinical practice. We assessed the efficacy and safety of raltegravir-based therapy in an Italian cohort of HIV/HCV co-infected patients. One hundred and forty patients with HIV/HCV co-infection initiating raltegravir from SCOLTA project (Surveillance Cohort Long-Term Toxicity Antiretrovirals) were examined. Of them, 43 were women, with mean age of 45.4. ±. 6.4. years; 65 (46%) had undetectable HIV-RNA. < 50. copies/mL and 75 (54%) HIV-RNA. ≥. 50. copies/mL. According to CDC classification, 49 (35%) were in stage C. Based on Fib4 score at the time of starting raltegravir, patients were classified in class I in 41 cases, class II in 68 and in class III in 31 cases. Globally, the Fib4 score slightly decreased during 24. months follow-up, from 2.2 to a value of 1.8. Hepatic adverse events of any grade were observed in 67 patients, of which only 2 cases (3%) had severe liver toxicity (grade 3-4). Only one patient had to discontinue the therapy because of adverse events. According to univariate analysis, being in CDC stage C represented a risk for the development of liver toxicity, with a hazard ratio (HR) of 2.27 (95% CI 1.06-4.84, P= 0.033). None of the other variables considered (age, sex, years since detection of HIV and HCV-RNA detectable, years of previous HIV therapy, concomitant therapy with PI or NRTI, CD4+ cell count, Fib4, and transaminases level at baseline) resulted statistically correlated to the outcome. In conclusion, raltegravir-based regimens can be safely used in HCV infected patients; in this study, the hepatic toxicity has been found to be more frequent in patients with an advanced HIV disease (CDC stage C), independently of HIV-RNA suppression at raltegravir initiation.

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results